Long survival after immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma: A case report and review of literature

Figure 1 Patient's treatment history and outcome. A: Timeline: Treatment regimens with response assessment and carbohydrate antigen 199 change; B: Computed tomography (CT) of the abdominal and lung lesions throughout therapy. July 2019, CT images of lung and liver on presentation, benign proliferative lesion of lung was considered at that time; September 2019, CT images of lung and liver after 2 cycles of GemCis chemotherapy, the intrahepatic and intrapulmonary lesions were significantly larger than before, and the peritoneal lesions were increased and pleural effusion appeared; January 2020, CT images of lung and liver after 6 cycles of paclitaxel and programmed death 1 monoclonal antibody, lesions of liver and lung were clinical complete remission; C: Genomic alteration assay result; D: The Reactive cutaneous capillary endothelial proliferation developed in the oral gingiva after the third cycle of camrelizumab with paclitaxel and was surgically removed after 2 mo. iCC: Intrahepatic cholagiocarcinama cancer; PR: Partial response; PD: Progressive disease; cCR: Clinical complete remission; GemCis: Gemcitabine and cisplatin; IO: Immunotherpay; Pac: Paclitaxel; PD-1: Programmed death 1.